dodekin
Term · Oncology and biomedicine · MLC-T-ONC-013129
A human antibody-cytokine fusion protein composed of the recombinant form of the endogenous immunostimulatory cytokine interleukin-12 (IL-12) fused, in tandem diabody format, to the N-terminus of the human monoclonal antibody L19 specific for the extra-domain B of fibronectin (ED-B), with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of dodekin targets and binds to fibronectin-expressing cells in the tumor vasculature, thereby delivering IL-12 directly to the tumor vasculature. In turn, the IL-12 moiety targets, binds to and activates its cell-surface receptor, and activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. This may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. ED-B of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is over-expressed in the extracellular matrix and blood vessels of a majority of aggressive solid human tumors. It is not detectable in normal vessels and tissues.
| Identifier | MLC-T-ONC-013129 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | antibody-cytokine fusion protein IL12-L19L19; human monoclonal antibody-cytokine fusion protein IL12-L19L19; immunocytokine IL12-L19L19 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013129",
"term": "dodekin",
"field": "Oncology and biomedicine",
"definition": "A human antibody-cytokine fusion protein composed of the recombinant form of the endogenous immunostimulatory cytokine interleukin-12 (IL-12) fused, in tandem diabody format, to the N-terminus of the human monoclonal antibody L19 specific for the extra-domain B of fibronectin (ED-B), with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of dodekin targets and binds to fibronectin-expressing cells in the tumor vasculature, thereby delivering IL-12 directly to the tumor vasculature. In turn, the IL-12 moiety targets, binds to and activates its cell-surface receptor, and activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. This may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. ED-B of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is over-expressed in the extracellular matrix and blood vessels of a majority of aggressive solid human tumors. It is not detectable in normal vessels and tissues.",
"synonyms": [
"antibody-cytokine fusion protein IL12-L19L19",
"human monoclonal antibody-cytokine fusion protein IL12-L19L19",
"immunocytokine IL12-L19L19"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dodekin/"
}
Record 6,156 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.